- Home
- XGN vs FATE Comparison
XGN vs FATE Comparison
Compare XGN & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XGN
- FATE
- Stock Information
- Founded
- XGN 2002
- FATE 2007
- Country
- XGN United States
- FATE United States
- Employees
- XGN N/A
- FATE N/A
- Industry
- XGN Medical Specialities
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- XGN Health Care
- FATE Health Care
- Exchange
- XGN Nasdaq
- FATE Nasdaq
- Market Cap
- XGN 138.3M
- FATE 133.0M
- IPO Year
- XGN 2019
- FATE 2013
- Fundamental
- Price
- XGN $6.84
- FATE $1.30
- Analyst Decision
- XGN Strong Buy
- FATE Hold
- Analyst Count
- XGN 2
- FATE 8
- Target Price
- XGN $7.50
- FATE $4.14
- AVG Volume (30 Days)
- XGN 374.9K
- FATE 1.8M
- Earning Date
- XGN 05-05-2025
- FATE 05-13-2025
- Dividend Yield
- XGN N/A
- FATE N/A
- EPS Growth
- XGN N/A
- FATE N/A
- EPS
- XGN N/A
- FATE N/A
- Revenue
- XGN $56,724,000.00
- FATE $13,335,000.00
- Revenue This Year
- XGN $19.39
- FATE N/A
- Revenue Next Year
- XGN $13.27
- FATE N/A
- P/E Ratio
- XGN N/A
- FATE N/A
- Revenue Growth
- XGN 1.78
- FATE 105.85
- 52 Week Low
- XGN $1.71
- FATE $0.66
- 52 Week High
- XGN $7.20
- FATE $5.92
- Technical
- Relative Strength Index (RSI)
- XGN 62.02
- FATE 57.89
- Support Level
- XGN $6.51
- FATE $1.21
- Resistance Level
- XGN $7.20
- FATE $1.38
- Average True Range (ATR)
- XGN 0.51
- FATE 0.12
- MACD
- XGN 0.04
- FATE 0.02
- Stochastic Oscillator
- XGN 81.15
- FATE 82.36
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.